Shanghai, June 9, 2026 — Henlius (2696.HK) announced that the New Drug Application (NDA) for a new indication of its self-developed anti-PD-1 monoclonal antibody(mAb) HANSIZHUANG (serplulimab, trade name in Europe: Hetronifly^®) , in combination with Oxaliplatin and S-1 for neoadjuvant treatment of resectable gastric cancer with tumour PD-L1 expression CPS ≥ 5, followed by adjuvant monotherapy after surgery, has been officially approved by the China National Medical Products Administration (NMPA) under the priority review pathway.

On May 29, 2026, Henlius (2696.HK) announced that the New Drug Application (NDA) for its independently developed pertuzumab biosimilar HANBEIYOU (trade name in US and Europe: POHERDY^®) has been approved by the National Medical Products Administration (NMPA). It is indicated for neoadjuvant and adjuvant treatment of HER2-positive early-stage breast cancer and for the treatment of metastatic breast cancer, covering all indications approved in the Chinese Mainland for the reference pertuzumab injection. The approval signifies that the product has now been approved in the three major markets of China, the European Union, and the United States. Furthermore, Henlius' HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac^® in Europe) and HANBEIYOU have become the first domestic trastuzumab-pertuzumab dual-target combination approved in China, the US, and the EU. This critical milestone further solidifies the company's leading position in the comprehensive, full-course and global layout in the field of breast cancer treatment.

On 27 May 2026, Fortune China magazine released its 2026 list of “Most Admired Chinese Companies”, in which Fosun International Limited (“Fosun International” or the “Company”) (HKEX stock code: 00656) was included in the Industry Star List. This highlights Fosun’s outstanding performance and industry leadership in environmental, social, and corporate governance (ESG), employee responsibility, and value creation for stakeholders.

On 21 May 2026, S&P Global hosted the “Sustainability Yearbook (China Edition) 2026 Launch Ceremony and Sustainability Forum” in Shanghai. Fosun International Limited (Hong Kong Stock Exchange stock code: 00656, “Fosun International”) was included in the S&P Global Sustainability Yearbook (China Edition) 2026 and ranked among China’s Top 1% for the third consecutive year, recognizing its long-standing commitment to advancing environmental, social and governance (ESG) practices. This achievement underscores Fosun International’s industry-leading position in sustainability management and ESG efforts.

(Shanghai, China and Seongnam-si, South Korea, 13 May, 2026) – On 13 May, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196.SH, 02196.HK) and AriBio Co., Ltd. (“AriBio”), a biopharmaceutical company focused on neurodegenerative diseases, today jointly announced the signing of an exclusive global option agreement for the development, registration, manufacturing and commercialization of AR1001, an innovative drug candidate for the treatment of Alzheimer’s disease (AD).

Shanghai, China – May 10, 2026 – Shanghai Henlius Biotech, Inc. (2696.HK) today announced that its self-developed anti-PD-1 monoclonal antibody, serplulimab (European trade name: Hetronifly^®)

Shanghai, China – May 4, 2026 – Shanghai Henlius Biotech, Inc. (2696.HK) today announced that its innovative anti-PD-L1 antibody–drug conjugate (ADC), HLX43, has been permitted by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) to conduct the HLX43-NSCLC302 study — an international, multicenter phase 2/3 clinical trial in patients with advanced squamous non-small cell lung cancer (sqNSCLC). The trial will be conducted across multiple countries, including China, the United States, and Japan. The phase 3 stage is expected to serve as the first pivotal registration study for HLX43 and represents a significant milestone for HLX43 in the field of NSCLC, poised to offer a new therapeutic option for refractory sqNSCLC patients who have progressed on prior standard therapies.

(Hong Kong, 28 April 2026) Fosun International Limited (HKEX stock code: 00656, “Fosun International”), together with its subsidiaries (“Fosun” or the “Group”), released the Environmental, Social and Governance (ESG) Report 2025 (the “ESG Report”). Facing the increasingly severe challenges of global climate change, Fosun released its fourth Climate Information Disclosures Report with reference to Part D (“New Climate Requirements”) of Appendix C2 “Environmental, Social and Governance Reporting Code” of the Main Board Listing Rules of the Hong Kong Stock Exchange, the framework of the Task Force on Climate-Related Financial Disclosures (TCFD) recommendations and the International Financial Reporting Standards S2 Climate-related Disclosures Requirements (“IFRS S2”).

For 2026, the World Health Organization (WHO) has designated the theme for this year’s World Malaria Day as “Driven to End Malaria: Now We Can. Now We Must”, calling on the global community to seize the moment and accelerate efforts, in the fight for a malaria-free future.